Navigation Links
Phosphatase in Medical Technology

Drug Development Program Started Based on CAP(R) Human Cell Line

... of the Theraptech project is to develop a recombinant human alkaline phosphatase (rhuAP) using the novel versatile human CAP(R) cell line, which has been ... diseases. Based on a the anti-inflammatory mechanism of action of alkaline phosphatase towards e.g. TNFa, IL-6 and IL-8, as shown in both pre-clinical and ...

VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor

... IIa study of Lenocta(TM) (sodium stibogluconate), a novel protein tyrosine phosphatase inhibitor, in combination with interferon alpha, an immune stimulant ... against a wide spectrum of cancers. About PTPases The protein tyrosine phosphatase superfamily of enzymes functions in a coordinated manner with protein ...

Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting

... presentation of preclinical data, "Trodusquemine is a Protein Tyrosine phosphatase 1B Inhibitor that Causes Differential Weight Loss," provides ... inhibit the established and validated enzyme target, protein tyrosine phosphatase 1B (PTP-1B). The dual locations of MSI-1436 action make the drug a ...

DaVita Abstracts Accepted Into National Kidney Foundation's 2009 Spring Symposium

... Torrance, CA; (2)Salem VA Medical Center, Salem, VA; and (3)DaVita Inc, El Segundo, CA -- Title: Association of Serum Alkaline phosphatase and Coronary Artery Calcification in Hemodialysis Patients Authors: Ronney Shantouf(1), Mehdi Rambod(1), Csaba P Kovesdy(2), ...

Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)

... in two previous phase 1 studies. About Trodusquemine (MSI-1436) Trodusquemine is the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme central to controlling the function of both the leptin and insulin pathways. By inhibiting both central and peripheral PTP1B, ...

Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia

... via this route later this year." About Trodusquemine (MSI-1436) Trodusquemine is the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme central to controlling the function of both the leptin and insulin pathways. By inhibiting both central and peripheral PTP1B, ...

Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer

... across the three dose levels; 25 kBq/kg, 50 kBq/kg and 80 kBq/kg, respectively. The secondary, but important, endpoint of bone-specific alkaline phosphatase (b-ALP) also showed a significant dose-dependent effect between the lowest and the two higher dose levels, as well as confirming once more the strong ...

FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation

... (fospropofol disodium) Injection is a proprietary water-soluble prodrug of propofol that, after intravenous injection, is converted by alkaline phosphatase enzymes in the body into propofol. LUSEDRA is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult ...

Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease

... stops ambulation. About ENB-0040 ENB-0040 is a fusion protein that includes the catalytic domain of human tissue non-specific alkaline phosphatase (TNSALP), and a patented peptide used to target the enzyme to bone. The preclinical studies of ENB-0040 in the "knockout" mouse model of severe ...

Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics

... Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), an enzyme central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP1B, MSI-1436 is expected to ...

Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team

... some cases stops ambulation. About ENB-0040 ENB-0040 is a fusion protein that includes the catalytic domain of human tissue non-specific alkaline phosphatase (TNSALP), and a patented peptide used to target the enzyme to bone. Preclinical studies of ENB-0040 in the "knockout" mouse model of severe ...

Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040

... some cases stops ambulation. About ENB-0040 ENB-0040 is a fusion protein that includes the catalytic domain of human tissue non-specific alkaline phosphatase (TNSALP), an immunoglobulin Fc domain and a patented anionic peptide used to target the enzyme to bone. Preclinical studies of ENB-0040 in the ...

Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia

... some cases stops ambulation. About ENB-0040 ENB-0040 is a fusion protein that includes the catalytic domain of human tissue non-specific alkaline phosphatase (TNSALP), and a patented peptide used to target the enzyme to bone. Preclinical studies of ENB-0040 in the "knockout" mouse model of severe ...

Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting

... in Snowmass Village, Colorado. The poster presentation entitled, "Trodusquemine (MSI-1436), An Allosteric Inhibitor of Protein Tyrosine phosphatase 1B," concluded that MSI-1436 is a selective, reversible and noncompetitive inhibitor of PTP-1B that enhances insulin signaling through potent PTP-1B ...

New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma

... (incidence greater than or equal to 30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated AST (38%), and leukopenia (32%). ...

New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer

... (incidence greater than or equal to 30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated AST (38%), and leukopenia (32%). ...

Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer

... (incidence greater than or equal to 30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated AST (38%), and leukopenia (32%). ...

Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting

... undesirable as weight- loss drugs since they affect locomotor behavior and may have high addictive potential. MSI-1436 is a protein tyrosine phosphatase 1B inhibitor (PTP-1B), which increases insulin sensitivity and reduces food intake in animals, and is currently in clinical development for ...

Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer

... (incidence greater than or equal to 30%) are anemia (94%), hyperglycemia (89%), hyperlipemia (87%), hypertriglyceridemia (83%), elevated alkaline phosphatase (68%), elevated serum creatinine (57%), lymphopenia (53%), hypophosphatemia (49%), thrombocytopenia (40%), elevated AST (38%), and leukopenia (32%). ...

Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting

... first drug candidate that acts both centrally and peripherally to selectively inhibit the established and validated enzyme target, protein tyrosine phosphatase 1B (PTP-1B). The dual locations of MSI-1436 action make the drug a promising candidate for both type 2 diabetes and obesity. By inhibiting PTP-1B, ...

Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting

... first drug candidate that acts both centrally and peripherally to selectively inhibit the established and validated enzyme target, protein tyrosine phosphatase 1B (PTP-1B). The dual locations of MSI-1436 action make the drug a promising candidate for both type 2 diabetes and obesity. By inhibiting PTP-1B, ...

Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference

... first drug candidate that acts both centrally and peripherally to selectively inhibit the established and validated enzyme target, protein tyrosine phosphatase 1B (PTP-1B). The dual locations of MSI-1436 action make the drug a promising candidate for both obesity and type 2 diabetes. By inhibiting PTP-1B, ...

AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial with Alkaline Phosphatase in Acute Renal Failure

... a subgroup of a Phase IIa trial with Alkaline phosphatase to treat Sepsis. Plasma creatinine clearance, a ... with Acute Renal Failure treated with Alkaline phosphatase and deteriorated by 25% (median) in patients with ... We now plan to explore the use of Alkaline phosphatase in Acute Renal Failure in a separate study." ...

AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

... results of its Phase IIa Alkaline phosphatase (AP) trial for patients with ulcerative colitis, ... II clinical trials for two products; Alkaline phosphatase for sepsis, acute renal failure and ulcerative ... partners for its products. About Alkaline phosphatase (AP) The endogenous enzyme ...

Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research

... at 18-month follow-up -- Hepatotoxicity, as evidenced in the adjuvant study by increase in transaminases and alkaline phosphatase was observed more commonly in the Eloxatin(R) combination arm. The incidence of increased bilirubin was similar on both arms. Changes ...

Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment

... adverse events (grades 3/4) with GEMZAR for the first- line treatment of patients with pancreatic cancer were neutropenia (24%-26%); alkaline phosphatase elevation (16%-20%); AST elevation (12%-17%); nausea/vomiting (12%-13%); ALT elevation (10%-11%); anemia (10%); leukopenia (9%-10%); thrombocytopenia ...

The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer

... paresthesia at 18-month follow-up * Hepatotoxicity, as evidenced in the adjuvant study by increase in transaminases and alkaline phosphatase was observed more commonly in the Eloxatin(R) combination arm. The incidence of increased bilirubin was similar on both arms. Changes ...

Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting

... Menadione, a small organic molecule, has been shown to activate the Epidermal Growth Factor Receptor (EGFR) signaling pathway by inhibiting phosphatase activity. EGFR inhibitors or EGFRIs are currently used to treat non-small cell lung cancer, pancreatic, colorectal, and head & neck cancer. ...

Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions

... (MSI-1436) Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP-1B). PTP-1B is central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP-1B, MSI-1436 is expected to ...
Other Contents
(Date:8/29/2014)... repeated climatic shifts over the last 120,000 years ... a team of researchers led by City College ... a new biodiversity metric called "phylogeographic endemism." , ... variation within species is restricted in geographical space. ... and 14 other researchers from institutions in Brazil, ...
(Date:8/29/2014)... available in German . ... the natural nitrogen cycle on Earth and in biological ... thought to depend on nitrite as their source of ... Daims, a microbiologist at the University of Vienna, has ... an alternative source of energy. The oxidation of hydrogen ...
(Date:8/29/2014)... phytoplankton, such as the prolific bloomer Emiliania huxleyi ... have discovered. The finding contradicts the common view that ... depend on scarce supplies of thiamine in the ocean ... think about the ocean," says CIFAR Senior Fellow ... paper with CIFAR fellows John Archibald ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3
(Date:8/29/2014)... August 29, 2014 As reported by WKMS.com ... Recovery , an Ohio municipal court drug has come up ... Fred Moses, who serves as the presiding judge in a ... makers to offer addicts a medicated treatment option that can ... the drug known as Vivitrol, which blocks receptors in the ...
(Date:8/29/2014)... 29, 2014 According to new research presented ... Peer Pressure, Key to Prescription Drug Misuse Among Young Adults ... for 18-29 year olds when it comes to prescription drug ... this age group the real problem which influences misuse of ... and recreational use of them to have fun with other ...
(Date:8/29/2014)... Dallas, Texas (PRWEB) August 30, 2014 ... Glass microfiber Industry, 2009-2019 is a professional and ... microfiber industry. The report firstly reviews the basic ... and manufacturing technology. The report then explores global ... their product specification, capacity, Production value, and market ...
(Date:8/29/2014)... 2014 Healthpointe has unveiled its new ... the convenience of visiting with physicians online. Anyone can ... , Healthpointe doctors are always available and happy to ... the doctor can even see the patient’s entire family. ... or she can prescribe medications that are available for ...
(Date:8/29/2014)... August 29, 2014 Healthpointe is ... University Physical Therapy students via Clinical Rotations. ... will be shadowing Healthpointe providers and specialists throughout ... to develop clinical experience and learn professional preparation. ... will gain insight into several patient care techniques ...
Breaking Medicine News(10 mins):Health News:Ohio Judge Pushes for Addiction Recovery Tool 2Health News:Ohio Judge Pushes for Addiction Recovery Tool 3Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Virtual Doctor’s Appointments Now Available at Healthpointe 2Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2
Other TagsOther Tags